Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15191795 | 0.90 | MAPT (0.49) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL3712221 | 0.90 | MAPT (0.49) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL1796551 | 0.89 | MAPT (0.47) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL7611290 | 0.84 | MAPT (0.53) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL4414189 | 0.84 | MAPT (0.55) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL7608758 | 0.83 | MAPT (0.51) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL10366613 | 0.83 | ALDH1A1 (0.52) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL25267950 | 0.81 | MAPT (0.53) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| SCHEMBL9673198 | 0.81 | CYP4A11 (0.58) | MAPTALDH1A1KMT2ARAB9ACA1 | |
| Hydrochloric Acid SCHEMBL443786 | 0.81 | LOXL2 (0.54) | MAPTALDH1A1KMT2ARAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228325-A1 | ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-0683781-B1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | METABASIS THERAPEUTICS INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20020173515-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2002-11-21 | — | — | US | disclosed |
| US-6323210-B2 | TRANSFERASE INHIBITOR | AGOURON PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| US-6207670-B1 | USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI | AGOURON PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5945427-A | INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICRORGANISMS SUCH AS FUNGI, BACTERIA AND YEASTS; TREATMENT FOR TUMORS, INFLAMMATION, PSORIASIS; IMMUNOSUPPRESSIVE ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5739141-A | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5731432-A | Inhibitors of adenosine monophosphate deaminase | GENSIA SICOR INC. (US) | 1998-03-24 | — | — | US | disclosed |
| US-5726312-A | Methods for preparing antiproliferative 5-substituted pyrimidone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0683781-A4 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE. | GENSIA PHARMA (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0683781-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA PHARMACEUTICALS, INC. (US) | 1995-11-29 | — | — | EP | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994018200-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228325-A1 | ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR3 | MAPT 3173/4885ALDH1A1 2942/4885KMT2A 4039/4885 |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | MAPT 2714/4885ALDH1A1 250/4885KMT2A 909/4885 |
| US-20020173515-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | MAPT 2714/4885ALDH1A1 250/4885KMT2A 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.